Table 1
Parameter | Outcome | |
|---|---|---|
NVP lead in dose initiated patients | 3647 (n) | |
Male | 2408(66.02%) | |
Female | 1239(33.97%) | |
Male with CD4 >400 cells/mm3 and initiated NVP lead in dose (n = 2408) | 47(1.95%) | |
Female with CD4 >250 cells/mm3 and initiated NVP lead in dose (n = 1239) | 112(9.03%) | |
NVP induced Rash | Male (n = 47) | 0 |
Female (n = 112) | 5(4.46%) | |
NVP induced Hepatitis | Male (n = 47) | 1(2.12%) |
Female (n = 112) | 0 | |
Male with CD4 <400 cells/mm3 and initiated NVP lead in dose (n = 2408) | 1629(67.64%) | |
Female with CD4 <250 cells/mm3 and initiated NVP lead in dose (n = 1239) | 838(67.63%) | |
NVP induced Rash | Male (n = 1629) | 19(1.16%) |
Female (n = 838) | 15(1.78%) | |
NVP induced Hepatitis | Male (n = 1629) | 5(0.30%) |
Female (n = 838) | 2(0.23%) | |